UNASSIGNED: We report a case of a patient with uncontrolled severe asthma and other T2 inflammatory diseases (atopic dermatitis, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) treated with dupilumab.
UNASSIGNED: After one year of treatment, dupilumab improved asthma control together with lung function parameters and airway inflammation. Additionally, a positive impact on quality of life (QoL), evaluated by validated questionnaires, across all the diseases was observed.
UNASSIGNED: In this case report, a positive and objectively measurable of global improvement on QoL across all four T2 comorbidities was observed after treatment with dupilumab, demonstrating the important role of IL-4 and IL-13 and the existence of a unifying pathological mechanism in T2 diseases.
■治疗一年后,dupilumab改善了哮喘控制以及肺功能参数和气道炎症.此外,对生活质量(QoL)的积极影响,通过经过验证的问卷进行评估,所有的疾病都被观察到了。
■在此案例报告中,在使用dupilumab治疗后,观察到所有四种T2合并症的QoL总体改善,证明了IL-4和IL-13在T2疾病中的重要作用以及统一的病理机制的存在。